Aloracetam
From Self-sufficiency
| 220px | |
| Systematic (IUPAC) name | |
|---|---|
|
N-[2-(3-formyl-2,5-dimethylpyrrol-1-yl)ethyl]acetamide | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 119610-26-3 |
| ATC code | none |
| PubChem | CID 178134 |
| Chemical data | |
| Formula | C11H16N2O2 |
| Molar mass | 208.257 g/mol[[Script error: No such module "String".]] |
| Script error: No such module "collapsible list". | |
Aloracetam is a nootropic drug of the racetam family, developed by Aventis for the treatment of Alzheimer's disease.[1]
See also
References
- ↑ Fischer F, Matthisson M, Herrling P. List of Drugs in Development for Neurodegenerative Diseases. Neurodegenerative Diseases 2004;1:50–70.
| 35px | This drug article relating to the nervous system is a stub. You can help ssf by expanding it. |
| 30px | This article about an organic compound is a stub. You can help ssf by expanding it. |
Categories:
- Pages with script errors
- Pages with broken file links
- Infobox drug tracked parameters
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs not assigned an ATC code
- Articles containing unverified chemical infoboxes
- 2Fix
- Racetams
- Pyrroles
- Aldehydes
- Acetamides
- Nervous system drug stubs
- Organic compound stubs
